Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapies

Executive Summary

Part 1: Scrip spoke with companies working on cell and gene therapies and novel neuroscience platforms – areas difficult to finance in the past, but seeing increasing investor interest – about funding challenges and opportunities in 2019.

You may also be interested in...



Finance Watch: BIO Says Proposed Foreign Investment Regulations Will Lower Investment In US Biotech

Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.

Kiadis Buying CytoSen Will Combine Natural Killer And T-Cell Immunotherapies

An all-stock transaction will see Europe’s Kiadis and US’s CytoSen bring together complementary approaches to improving stem cell transplants and cancer immunotherapy.

United Neuroscience To Move Forward Alzheimer's Vaccine After Promising Phase IIa

It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC124600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel